Author + information
- Ronstan Loboa,b,
- Kirsten Mannixa,b,
- Catriona Aherna,b,
- Ailish Hannigana,b,
- Syed Abbasa,b,
- Terence Hennessya,b,
- Thomas B. Meanya,b and
- Thomas J. Kiernana,b
Background: The ticagrelor molecule resembles adenosine. Ticagrelor may exert pleiotropic actions, beyond platelet inhibition, which are possibly adenosine-mediated. It has been suggested that in patients with coronary artery disease (CAD), ticagrelor may influence endothelial function. The aim of this study was to assess the effects of ticagrelor on endothelial function.
Methods: Patients undergoing percutaneous coronary intervention (PCI) for CAD (electively or for acute coronary syndrome) were recruited. Patients were randomized to either ticagrelor or clopidogrel within 24 hours after PCI (week 0). Endothelial function was assessed on week 4 using Peripheral Arterial Tonometry (EndoPat 2000 system, Itamar Medical, Caesarea, Israel). The device measured the Reactive Hyperemia Index (RHI; a measure of endothelial responsiveness) and Augmentation Index (AI; a measure of arterial stiffness). Endothelial dysfunction was defined as a RHI <1.67. The patients were then crossed over to the alternative antiplatelet for 5 weeks (4 weeks plus a 1 week washout). On week 9, endothelial function was reassessed.
Results: The study recruited 62 patients. There were no statistically significant differences between ticagrelor and clopidogrel for RHI or AI (Table). There was a trend towards higher AI for ticagrelor compared to clopidogrel (95% CI: −0.13% – 5.32%, p=0.06).
Conclusion: In patients undergoing PCI for CAD, there was no difference in endothelial function between ticagrelor and clopidogrel.
Poster Hall, Hall C
Friday, March 17, 2017, 3:45 p.m.-4:30 p.m.
Session Title: Revascularization and Myocardial Preservation in Acute and Stable Ischemic Heart Disease
Abstract Category: 3. Acute and Stable Ischemic Heart Disease: Therapy
Presentation Number: 1165-315
- 2017 American College of Cardiology Foundation